THERAtRAME’s Post

In March, we welcomed the following Members to the BIA community 📌 The BBIA unites those working in the bio-based and #biodegradable industries, through advocacy, collaboration and education, to put the industrial #bioeconomy at the centre of #Sustainability and #Economic growth in the UK. 📌 The CEPI (Coalition for Epidemic Preparedness Innovations) aims to accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. 📌 EnsiliTech is a #biotech startup applying its patented platform technology, to store and transport biologicals without refrigeration or freezing. 📌 EyeBio is developing a new generation of therapies to protect, restore, and improve vision for people living with eye diseases. 📌 Kuano is a drug discovery company combining Quantum simulations and #AI to create superior therapies. 📌 MOMO Biotech is creating the most accurate tumour shield model and challenging it with innovative drug modalities. 📌 PCD Research is a medical research charity that works to advance the health of children and adults with Primary Ciliary Dyskinesia, involving inherited motile or non-motile ciliary dysfunction. 📌 Sanna Science is shaping the future of safe and effective phototherapeutics with the clinically validated formulations of isolated cannabinoids. 📌 Sofinnova Partners is a leading European venture capital firm with 50 years of experience in life science investing, specialising in #healthcare and #sustainability. Interested in joining the BIA, click here to find out more ➡️ https://ow.ly/jzV550QJSmc

Day 18 of the 30 - DAY Helix Biogen Challenge When we started the project for the development of the vaccine candidate, it was something I was so new to and I had to pay close attention to what was taught and what I needed to know. Individually, we will be given tasks and we had to deliver them as soon as possible. Knowing fully well that this was new to me, I had to do more findings and taught about things that will give me the results I needed and with the help of my friends and colleagues, I was able to achieve those tasks. Dr. Oladipo Elijah Kolawole (Ph.D) Helix Biogen Institute #HelixBiogenInstitute #HelixBiogenChallenge #ScientificChallenge

Ask me today how to get a low-cost pilot study with up to 15 mice to jumpstart your pre-clinical research! #preclinical #pharmacology #mice #humanizedmice #pilotstudy #IND

Spotlight on Afrobodies! Afrobodies are shaping the future of diagnostics and therapeutics by producing recombinant alpaca antibodies (AfroBodies™) to supply the local and global life sciences, diagnostics, and therapeutics markets. A leader in their field, Afrobodies recognised gaps in the global market as well as Africa's reliance on imported antibodies. This prompted them to start their mission of empowering researchers worldwide. Their unique approach focuses on developing recombinant alpaca antibodies with distinct amino acid sequences and offering tailored discovery services. Having experienced significant development over the past few years, they aspire to continue on their growth trajectory, with plans to expand into Europe. Afrobodies, who are currently tenants at our UVU Bio Lab, were one of 12 winners at the 2023 Irish Tech Challenge South Africa and are set to participate in an acceleration programme at Dublin’s Dogpatch Labs startup and innovation hub. Follow their page to stay updated on their transformative journey and impactful contributions to the global health tech landscape. #Afrobodies #BiotechInnovation #FoundersFriday

My heartfelt gratitude to the 51 Pharma and Biotech companies, as well as the National Institutes of Health (NIH), for engaging in insightful discussions during the One-on-One Partnering Program at BIO2024. Their keen interest in our Multiomics and Biomimetic Digital Twin Ecosystem analysis is truly inspiring, underscoring the importance of collaborative innovation in the healthcare industry. Through the publication of peer-reviewed papers, we have showcased the transformative impact of our work: - Enhanced pathophysiology understanding of diseases - Commencement of reclassification of variants of unknown clinical significance (VUSs) - Potential reduction in drug development time and costs by approximately 25-35% A significant milestone in our journey is the establishment of a partnership with the NIH for groundbreaking research on rare diseases. Looking forward to continued collaboration and advancements in healthcare that benefit patients worldwide. #Biotech #Pharma #HealthcareInnovation #Collaboration #Research #BIO2024

🚀 Exciting news from Informuta! They have just secured a $275,000 award from the National Science Foundation (NSF) for their groundbreaking work in antibiotic resistance diagnostics. This award is part of the Small Technology Transfer Research Program Phase I. #SBIR #STTR 🔬 The project aims to develop a platform that leverages sequencing to identify and predict multidrug resistance. With antibiotic resistance becoming a global health crisis, this innovative approach could save millions of lives by predicting current and future drug resistance status. The project will focus on mutational signatures in bacteria, offering a species-agnostic solution that can detect emerging resistance mechanisms. #HealthcareInnovation #Biotech 📅 This grant will support Informuta's research for nearly a year, starting from September 15, 2024, and ending on August 31, 2025. Kudos to the team for their dedication to tackling one of the most pressing health issues of our time! #Research #Innovation

🌟 Exciting News for #BIO2024! 🌟 Dynamk Capital is thrilled to announce that Vernal Biosciences, one of our innovative portfolio companies, is exhibiting at the BIO 2024 conference! 🎉 At Dynamk Capital, we believe in empowering groundbreaking biotech companies that are shaping the future of healthcare. Vernal Biosciences is at the forefront of RNA synthesis technology, driving advancements in therapeutics and diagnostics. Their presence at BIO 2024 underscores the critical role they play in the biotech ecosystem. Here’s why this is important: 🔬 Innovation Showcase: Vernal Biosciences will highlight their cutting-edge RNA synthesis capabilities, providing insights into how their technology is revolutionizing the biotech industry. 🤝 Networking Opportunities: BIO 2024 is a premier event for the life sciences sector, offering unparalleled networking opportunities with industry leaders, investors, and potential partners. 🌍 Global Impact: By exhibiting at BIO 2024, Vernal Biosciences is positioned to expand their global reach and accelerate their mission to deliver transformative RNA-based solutions. We are proud to support Vernal Biosciences as they pave the way for the next generation of biotech innovations. Visit their booth at BIO 2024 and discover how they are making a difference in the world of life sciences! #BIO2024 #Biotech #Innovation #RNATechnology #DynamkCapital #VernalBiosciences #HealthcareInnovation

What does it take to create Europe's next globally leading biotech ecosystem, covering every step from groundbreaking research to successful commercialisation? This was the leading question at this year’s fireside panel discussion at the #DRFZBerlinSymposium2024.     Key takeaways from the panel discussion: Strong Consensus: Europe has the huge potential conducting groundbreaking research.      Issue: A significant gap exists in translating research from the lab to the clinic, especially due to complex regulatory frameworks.      Recommendation: Policymakers must simplify regulatory frameworks and provide clearer guidance to accelerate the path of new therapies to patients.     Thanks for this great exchange between our Joachim von Arnim and Eicke Latz (German Rheumatology Research Center) | Stefan Miltenyi (Miltenyi Biotec) | Luke O'Neill (Trinity College Dublin) | Jan-Philipp Kruse (Bayer) | Dr. Thorsten Lambertus (DEEP - ESMT Berlin) as well as moderator Marco Janezic (Blue Ribbon Partners)     #TissueTherapeutics #Cellbricks #Charité #MaxPlanckSociety #Ecosystem 

📆 In One Week: Don't miss the opportunity to connect with AcuraStem CEO, Sam Alworth, and Head of Target Validation, Wen-Hsuan (Wen) Chang, at the Target ALS Annual Meeting in Boston, from May 7—9. Sam and Wen will be onsite and available to discuss AcuraStem’s latest breakthroughs in ALS research. Learn more about AcuraStem’s patient-based approach and iNeuroRX® technology platform that is advancing highly promising therapeutic candidates for the treatment of ALS. Discover more about AcuraStem and our trail-blazing work in ALS research by visiting acurastem.com #TargetALS #ALS #drugdiscovery #AcuraStem